Avesthagen Limited's subsidiary company Avesta Biotherapeutics & Research Private Limited (ABRPL) has received clearance from the Review Committee for Genetic Manipulation (RCGM) authorized by the Department of Biotechnology, Government of India to enter into a pivotal pre-clinical safety and efficacy evaluation study for three of its biopharmaceutical product development programmes.

The Review Committee for Genetic Manipulation has approved ABRPL's applications for conducting a pre-clinical evaluation of these biopharmaceutical products at recognized contract research facilities.

These biopharmaceutical products are being developed as per global regulatory standards by ABRPL, a joint venture between Avesthagen and Meditab Specialities. It is targeted at important therapeutic indications like rheumatoid arthritis, anaemia resulting from chronic renal failure or chemotherapy and colorectal cancer.

The company is one of the pioneers in developing high-technology entry barrier products that will eventually be launched in the Indian market. The products will progress to clinical evaluation during early 2009 based on the outcome of the pre-clinical evaluation.